Treatment of Type 1 Diabetes with Anti-CD3 Monoclonal Antibody

Reviews in Endocrine and Metabolic Disorders

Volumn 4, Issue 4, 2003, Pages 361-368

  Glandt, Mariela ^a,b   Hagopian, William ^a,b   Herold, Kevan C ^a,b  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

Author keywords

Anti CD3 monoclonal antibody; Autoimmunity; Immune therapy; Type 1 diabetes mellitus

Indexed keywords

AZATHIOPRINE; C PEPTIDE; CD4 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FC RECEPTOR; GAMMA INTERFERON; HEMOGLOBIN A1C; IMMUNOGLOBULIN FC FRAGMENT; INSULIN; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; MONOCLONAL ANTIBODY CD3; OKT 3; PREDNISONE; STEROID;

AUTOIMMUNITY; CELL FUNCTION; CELL POPULATION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CLONAL ANERGY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIABETIC KETOACIDOSIS; DRUG MECHANISM; FEVER; FLU LIKE SYNDROME; GRAFT FAILURE; HEADACHE; HUMAN; HYPERTENSION; IMMUNE RESPONSE; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN RELEASE; LUNG EDEMA; MOUSE STRAIN; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PROTEIN CROSS LINKING; RASH; REGULATORY MECHANISM; REMISSION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

EID: 0344306537     PISSN: 13899155     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1027354129493     Document Type: Review

References (48)

1. Atkinson MA, Eisenbarth GS. Type 1 diabetes: New perspectives on disease pathogenesis and treatment. Lancet 2001;358(9277):221-229.
2. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: Observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group. J Clin Endocrinol Metab 1987;65(1):30-36.
3. Greenbaum CJ. Type 1 diabetes intervention trials: What have we learned? A critical review of selected intervention trials. Clin Immunol 2002;104(2):97-104.
4. Stiller CR, Dupre J, Gent M, Jenner MR, Keown PA, Laupacis A, Martell R, Rodger NW, von Graffenried B, Wolfe BM. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 1984;223(4643):1362-1367.
5. Bougneres PF, Carel JC, Castano L, Boitard C, Gardin JP, Landais P, Hors J, Mihatsch MJ, Paillard M, Chaussain JL, Bach JF. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med 1988;318(11):663-670.
6. Parving HH, Tarnow L, Nielsen FS, Rossing P, Mandrup-Poulsen T, Osterby R, Nerup J. Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study. Diabetes Care 1999;22(3):478-483.
7. Shizuru JA, Taylor-Edwards C, Banks BA, Gregory AK, Fathman CG. Immunotherapy of the nonobese diabetic mouse: Treatment with an antibody to T-helper lymphocytes. Science 1988;240(4852): 659-662.
8. Zhang J, Salojin KV, Delovitch TL. CD28 co-stimulation restores T cell responsiveness in NOD mice by overcoming deficiencies in Rac-1/p38 mitogen-activated protein kinase signaling and IL-2 and IL-4 gene transcription. Int Immunol 2001;13(3):377-384.
9. Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 1994;91(1):123-127.
10. Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 1997;158(6):2947-2954.
11. Chatenoud L, Bach JF. Anti-CD3 antibodies. Immunol Ser 1993;59:175-191.
12. Chatenoud L. OKT3-induced cytokine-release syndrome: Prevention effect of anti-tumor necrosis factor monoclonal antibody. Transplant Proc 1993;25(2 Suppl 1):47-51.
13. Chatenoud L, Ferran C, Legendre C, Thouard I, Merite S, Reuter A, Gevaert Y, Kreis H, Franchimont P, Bach JF. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 1990;49(4):697-702.
14. Hirsch R, Bluestone JA, Bare CV, Gress RE. Advantages of F(ab′)2 fragments of anti-CD3 monoclonal antibody as compared to whole antibody as immunosuppressive agents in mice. Transplant Proc 1991;23(1 Pt 1):270-271.
15. Herold KC, Bluestone JA, Montag AG, Parihar A, Wiegner A, Gress RE, Hirsch R. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes 1992;41(3):385-391.
16. Hirsch R, Gress RE, Pluznik DH, Eckhaus M, Bluestone JA. Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells. J Immunol 1989;142(3):737-743.
17. Smith JA, Tang Q, Bluestone JA. Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets. J Immunol 1998;160(10):4841-4849.
18. Smith JA, Tso JY, Clark MR, Cole MS, Bluestone JA. Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy. J Exp Med 1997;185(8):1413-1422.
19. Herold KC, Vezys V, Sun Q, Viktora D, Seung E, Reiner S, Brown DR. Regulation of cytokine production during development of autoimmune diabetes induced with multiple low doses of streptozotocin. J Immunol 1996;156(9):3521-3527.
20. Katz JD, Wang B, Haskins K, Benoist C, Mathis D. Following a diabetogenic T cell from genesis through pathogenesis. Cell 1993; 74(6):1089-1100.
21. Zipris D, Greiner DL, Malkani S, Whalen B, Mordes JP, Rossini AA. Cytokine gene expression in islets and thyroids of BB rats. IFN-gamma and IL-12p40 mRNA increase with age in both diabetic and insulin-treated nondiabetic BB rats. J Immunol 1996;156(3):1315-1321.
22. Xu D, Alegre ML, Varga SS, Rothermel AL, Collins AM, Pulito VL, Hanna LS, Dolan KP, Parren PW, Bluestone JA, Jolliffe LK, Zivin RA. In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol 2000;200(1):16-26.
23. Woodle ES, Xu D, Zivin RA, Auger J, Charette J, O'Laughlin R, Peace D, Jollife LK, Haverty T, Bluestone JA, Thistlethwaite JR, Jr. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 1999;68(5):608-616.
24. Utset TO, Auger JA, Peace D, Zivin RA, Xu D, Jolliffe L, Alegre ML, Bluestone JA, Clark MR. Modified anti-CD3 therapy in psoriatic arthritis: A phase I/II clinical trial. J Rheumatol 2002;29(9):1907-1913.
25. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002;346(22):1692-1698.
26. Linn T, Ortac K, Laube H, Federlin K. Intensive therapy in adult insulin-dependent diabetes mellitus is associated with improved insulin sensitivity and reserve: A randomized, controlled, prospective study over 5 years in newly diagnosed patients. Metabolism 1996;45(12):1508-1513.
27. Daneman D, Clarson C. Residual beta-cell function in children with type 1 diabetes: Measurement and impact on glycemic control. Clin Invest Med 1987;10(5):484-487.
28. Silverstein J, Maclaren N, Riley W, Spillar R, Radjenovic D, Johnson S. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med 1988;319(10):599-604.
29. Jaeger C, Brendel MD, Eckhard M, Bretzel RG. Islet autoantibodies as potential markers for disease recurrence in clinical islet transplantation. Exp Clin Endocrinol Diabetes 2000;108(5):328-333.
30. Bosi E, Braghi S, Maffi P, Scirpoli M, Bertuzzi F, Pozza G, Secchi A, Bonifacio E. Autoantibody response to islet transplantation in type 1 diabetes. Diabetes 2001;50(11):2464-2471.
31. Jiang H, Chess L. The specific regulation of immune responses by CD8+ T cells restricted by the MHC class Ib molecule, Qa-1. Annu Rev Immunol 2000;18:185-216.
32. Colovai AI, Ciubotariu R, Liu Z, Cortesini R, Suciu-Foca N. CD8(+)CD28(-) T suppressor cells represent a distinct subset in a heterogeneous population. Transplant Proc 2001;33(1-2):104-107.
33. Smith JA, Bluestone JA. T cell inactivation and cytokine deviation promoted by anti-CD3 mAbs. Curr Opin Immunol 1997;9(5):648-654.
34. Chatenoud L, Salomon B, Bluestone JA. Suppressor T cells - They're back and critical for regulation of autoimmunity! Immunol Rev 2001;182:149-163.
35. Boitard C, Yasunami R, Dardenne M, Bach JF. T cell-mediated inhibition of the transfer of autoimmune diabetes in NOD mice. J Exp Med 1989;169(5):1669-1680.
36. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA. B7/CD28 costimulation is essential for the homeostasis of the CD4+ CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000;12(4):431-440.
37. Yasunami R, Bach JF. Anti-suppressor effect of cyclophosphamide on the development of spontaneous diabetes in NOD mice. Eur J Immunol 1988;18(3):481-484.
38. Katz JD, Benoist C, Mathis D. T helper cell subsets in insulin-dependent diabetes. Science 1995;268(5214):1185-1188.
39. Herold KC, Burton JB, Francois F, Poumian-Ruiz E, Glandt M, Bluestone JA. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). J Clin Invest 2003;111(3):409-418.
40. Groux H, Bigler M, de Vries JE, Roncarolo MG. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J Exp Med 1996;184(1):19-29.
41. Pennline KJ, Roque-Gaffney E, Monahan M. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin Immunol Immunopathol 1994;71(2):169-175.
42. Zhang YC, Pileggi A, Agarwal A, Molano RD, Powers M, Brusko T, Wasserfall C, Goudy K, Zahr E, Poggioli R, Scott-Jorgensen M, Campbell-Thompson M, Crawford JM, Nick H, Flotte T, Ellis TM, Ricordi C, Inverardi L, Atkinson MA. Adeno-associated virus-mediated IL-10 gene therapy inhibits diabetes recurrence in syngeneic islet cell transplantation of NOD mice. Diabetes 2003;52(3):708-716.
43. Roncarolo MG, Bacchetta R, Bordignon C, Narula S, Levings MK. Type 1 T regulatory cells. Immunol Rev 2001;182:68-79.
44. Levings MK, Sangregorio R, Sartirana C, Moschin AL, Battaglia M, Orban PC, Roncarolo MG. Human CD25(+) CD4(+) T suppressor cell clones produce transforming growth factor beta, but not Interleukin 10, and are distinct from type 1 T regulatory cells. J Exp Med 2002;196(10):1335-1346.
45. Belghith M, Bluestone JA, Barriot S, Megret J, Bach JF, Chatenoud L. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 2003;9(9):1202-1208.
46. Sebastiani S, Allavena P, Albanesi C, Nasorri F, Bianchi G, Traidl C, Sozzani S, Girolomoni G, Cavani A. Chemokine receptor expression and function in CD4+ T lymphocytes with regulatory activity. J Immunol 2001;166(2):996-1002.
47. Dieckmann D, Bruett CH, Ploettner H, Lutz MB, Schuler G. Human CD4(+) CD25(+) regulatory, contact-dependent T cells induce interleukin 1-producing, contact-independent type 1-like regulatory T cells. J Exp Med 2002;196(2):247-253.
48. Levings MK, Sangregorio R, Roncarolo MG. Human cd25(+) cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 2001;193(11):1295-1302.